1. What Is the Pneumococcal Vaccine Market?
The Pneumococcal Vaccine Market covers the polysaccharide and conjugate vaccines targeting the Streptococcus pneumoniae bacteria that cause the pneumonia, meningitis, bacteraemia, and otitis media that contribute to millions of deaths annually. Children under 5 and adults over 65 are most vulnerable to the invasive pneumococcal disease that the vaccine prevents by generating antibodies against the polysaccharide capsule antigens that define the 90-plus pneumococcal serotypes. Conjugate vaccines link the polysaccharide to a carrier protein generating the T-cell-dependent immune response that protects infants whose immature immune systems cannot respond to polysaccharide alone. The pneumococcal vaccine market spans the 7-valent, 10-valent, 13-valent, 15-valent, and 20-valent protein conjugate vaccines that childhood immunisation programmes use for the infant primary series. The 23-valent polysaccharide vaccine remains in use for the adult population at risk of pneumococcal pneumonia. The pneumococcal vaccine market is being reshaped by the transition from 13-valent to the higher-valent 15-valent and 20-valent conjugate vaccines that cover the emerging serotypes including 15B, 22F, and 33F. These serotypes have increased in prevalence through the serotype replacement that the 13-valent vaccination has driven by eliminating vaccine-type carriage that made way for the non-vaccine serotypes.
2. Pneumococcal Vaccine Market Size & Forecast
3. Emerging Technologies
- Pneumococcal conjugate vaccine serotype replacement following the introduction of the 7-valent and 13-valent vaccines created the epidemiological shift where the non-vaccine serotypes including 19A, 3, 22F, and 33F increased in nasopharyngeal carriage and invasive disease. The vaccine-type serotypes were eliminated from the population by vaccination, making way for non-vaccine serotypes that the prior conjugate vaccines did not cover. This phenomenon has driven the development of higher-valent vaccines that expand coverage to the emerging serotypes.
- The 20-valent pneumococcal conjugate vaccine received FDA approval and CDC ACIP recommendation for adults 19 years and older as the preferred pneumococcal conjugate vaccine for the adult immunisation programme. This replaced the prior two-vaccine schedule of 13-valent conjugate followed by the 23-valent polysaccharide with the single 20-valent conjugate vaccine series, simplifying the adult pneumococcal vaccination programme. The consolidation to a single vaccine series has improved patient and provider compliance with adult pneumococcal vaccination.
- GAVI-funded pneumococcal vaccine access for the low income countries through the Advance Market Commitment guaranteed a minimum price to manufacturers who agreed to supply at the lower price to GAVI-eligible countries. This has expanded the pneumococcal conjugate vaccine coverage globally to over 150 countries by 2024, demonstrating the market incentive mechanism that the AMC used to accelerate pneumococcal vaccine availability. The countries that bear the majority of the pneumococcal disease burden are now the countries with the highest vaccination coverage through GAVI support.
- Pneumococcal whole-cell and protein-based vaccine candidates in development seek to provide the serotype-independent protection that the polysaccharide-based vaccines cannot achieve by targeting the common proteins shared across all pneumococcal serotypes. Serotype-independent coverage would eliminate the serotype replacement problem that conjugate vaccine expansion must continuously chase with higher-valent vaccine development. Conserved protein antigens including pneumolysin, PspA, and PspC are the primary targets for the next generation of universal pneumococcal vaccines.
Such innovations are driving change across adjacent industries too. Discover more in our Flu Vaccine Market.
4. Key Market Opportunity
Meaningful upside in the Pneumococcal Vaccine market involves higher-valency adult vaccination, where updated advisory committee recommendations for PCV20 and PCV15 for adults over 65 create a transition market from PPSV23 and PCV13. Companies with higher-valency conjugate vaccines capturing this adult recommendation sustain revenue through product upgrade. Complementary growth is driven by LMIC paediatric programme scale-up. As higher-valency adult vaccination proceeds and LMIC programmes expand, the addressable opportunity is growing across both the product transition in high-income adult markets and volume expansion in developing country paediatric programmes.
5. Top Companies in the Pneumococcal Vaccine Market
The following organisations hold leading positions in the Pneumococcal Vaccine Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Pfizer
- Merck
- GSK
- Sanofi
- GlaxoSmithKline
- Vaxcyte
- MinervaX
- Serum Institute of India
- CanSino Biologics
- Walvax Biotechnology
- Astellas Pharma
- Inventprise
6. Market Segmentation
The Pneumococcal Vaccine Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Type | PCV13 PCV15 PCV20 PPSV23 |
| By Age Group | Paediatric Adult Elderly |
| By Distribution | Government Procurement Private Pay |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Pneumococcal Vaccine Market trajectory over the forecast period:
PCV Serotype Replacement Following PCV7 and PCV13 Introduction Increasing Non-Vaccine Serotype 19A, 22F, and 33F Invasive Disease Has Driven PCV15 and PCV20 Development to Expand Coverage of the Emerging Serotypes That Previous Generations Enabled.Pfizer's PCV20 demonstrated non-inferior immunogenicity to Prevnar 13 plus non-inferiority to PPSV23 for unique serotypes in STRIDE-3 and STRIDE-5, and Merck's PCV15 demonstrated equivalent Prevnar 13 serotypes plus superior immunogenicity for serotypes 22F and 33F causing approximately 20% of adult invasive pneumococcal disease not prevented by Prevnar 13. ACIP's 2021 recommendation of either PCV15 or PCV20 for adults 65 and older created a binary prescribing decision, and Pfizer's commercial infrastructure and existing Prevnar franchise relationships have driven approximately 70% of new adult pneumococcal vaccine prescriptions toward Prevnar 20. The competitive serotype coverage advantage of PCV20 over Prevnar 13 reflects the commercial positioning of additional serotype breadth as the primary vaccine differentiation metric.
Prevnar 20 ACIP Adult Recommendation Replacing the Two-Vaccine PCV13 Then PPSV23 Sequential Schedule With Single-Agent 20-Valent Coverage Has Simplified the Adult Pneumococcal Immunisation Programme That the Prior Multi-Step Schedule Complicated.GAVI-supported PCV programmes in sub-Saharan Africa, South Asia, and Southeast Asia have vaccinated over 200 million children since 2009 launch, and retrospective post-implementation surveillance demonstrates 50-60% reduction in invasive pneumococcal disease hospitalisations. The WHO recommendation of 3+0 versus 2+1 schedules in high-mortality settings reflects immunological benefit of three-dose priming for establishing long-duration protective immunity in children at highest pneumococcal mortality risk during infancy. Serum Institute of India's pneumosil PCV10 prequalification providing an LMIC-priced alternative has reduced GAVI procurement cost from USD 7 to under USD 3 per dose, improving programme sustainability and enabling accelerated rollout.
GAVI Advance Market Commitment Guaranteeing Minimum Price to Manufacturers Supplying at LMIC-Affordable Prices Has Expanded Pneumococcal Conjugate Vaccine Access to 150-Plus Countries, Demonstrating the Market Incentive Mechanism That Accelerates Vaccine Access.GlaxoSmithKline's SPV-PCV23 combining capsular polysaccharide with common protein antigens including pneumococcal surface protein A and pneumolysin, and Affinivax's MAPS platform combining polysaccharide and protein antigens in multiantigen presentation format, represent the next vaccine design generation aiming for T-cell immunity against protein virulence factors shared across all strains. The serotype replacement phenomenon where Prevnar 13's elimination of 13 target serotypes allowed non-vaccine serotype expansion has sustained invasive pneumococcal disease despite high coverage, demonstrating the biological pressure that protein-based vaccines could circumvent by generating immunity against conserved virulence mechanisms rather than strain-specific capsules. Codagenix's live-attenuated pneumococcal vaccine and Pneumagen's attenuated whole-cell vaccine represent alternative approaches using the complete pneumococcal antigen repertoire that recombinant antigen vaccines cannot replicate from a subset of the proteome.
For related market intelligence, see the Vaccine Market.
8. Segmental Analysis
By type, the conjugate vaccine segment dominated the Pneumococcal Vaccine Market in 2025, as Pfizer's Prevnar 20 and Merck's Vaxneuvance anchored adult and paediatric immunisation with superior serotype coverage, generating the largest share of pneumococcal vaccine revenue.
By age group, the adult and older-adult segment is projected to register the highest growth rate through 2034, as twenty-valent and emerging broader formulations extend serotype coverage and recommendations expand routine pneumococcal vaccination to the large ageing population across high-income markets.
9. Regional Analysis
Regional demand patterns across the Pneumococcal Vaccine Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Pneumococcal Vaccine Market in 2025, accounting for approximately 47% of global revenue, attributed to the US premium pricing environment for Prevnar 20 and the adult recommendation driving commercial adoption at Pfizer and Merck. Moreover, the paediatric conjugate schedule is mature and fully implemented in North America. In addition, elderly vaccination at premium pricing sustains demand. Regional leadership is due to this combination of adult recommendation adoption and premium pricing.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Pneumococcal Vaccine Market through 2034, driven by expanding national paediatric pneumococcal programmes in China, India, and Southeast Asia and the large birth cohorts requiring vaccination and Gavi-supported procurement. The region is also witnessing adult pneumococcal vaccination recommendations expanding. Moreover, domestic vaccine manufacturing for pneumococcal vaccines is growing. The combination of these demand drivers and programme expansion positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Pneumococcal Vaccine Market was valued at USD 8.16 Bn in 2025 and is projected to reach USD 18.47 Bn by 2034, growing at a CAGR of 9.5% over the 2026–2034 forecast period.
The Pneumococcal Vaccine Market is projected to grow at a CAGR of 9.5% from 2026 to 2034.
North America dominated the Pneumococcal Vaccine Market in 2025, accounting for approximately 47% of global revenue, attributed to the US premium pricing environment for Prevnar 20 and the adult recommendation driving commercial adoption at Pfizer and Merck.
The leading companies in the Pneumococcal Vaccine Market include Pfizer, Merck, GSK, Sanofi, GlaxoSmithKline, Vaxcyte, MinervaX, Serum Institute of India, CanSino Biologics, Walvax Biotechnology, Astellas Pharma, Inventprise.
Pcv serotype replacement following pcv7 and pcv13 introduction increasing non-vaccine serotype 19a, 22f, and 33f invasive disease has driven pcv15 and pcv20 development to expand coverage of the emerging serotypes that previous generations enabled.
By type, the conjugate vaccine segment dominated the Pneumococcal Vaccine Market in 2025, as Pfizer's Prevnar 20 and Merck's Vaxneuvance anchored adult and paediatric immunisation with superior serotype coverage, generating the largest share of pneumococcal vaccine revenue.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.